OCUL logo

Ocular Therapeutix Inc. (OCUL)

$6.02

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OCUL

Market cap

$1.32B

EPS

-1.44

P/E ratio

--

Price to sales

31.81

Dividend yield

--

Beta

1.219579

Price on OCUL

Previous close

$6.01

Today's open

$5.98

Day's range

$5.81 - $6.27

52 week range

$5.81 - $16.44

Profile about OCUL

CEO

Pravin U. Dugel

Employees

325

Headquarters

Bedford, MA

Exchange

NASDAQ Global Market

Shares outstanding

220022840

Issue type

Common Stock

OCUL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on OCUL

Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript

Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility

Maintaining a "Buy" on Ocular Therapeutix, supported by FDA alignment on the AXPAXLI wet-AMD filing and opportunities to extend dosing and indications. The company expects Q4 2026 SOL-R 52-week interim safety data and an NDA submission; SOL-R's primary endpoint is expected in Q1 2028. In SOL-1, 74.1% of AXPAXLI patients maintained vision at week 36 versus 55.8% on EYLEA, achieving statistically significant superiority.

news source

Seeking Alpha • Nov 13, 2026

news preview

What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call

Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said on the company's third-quarter earnings call.

news source

MarketBeat • Nov 9, 2026

news preview

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without early persistent retinal fluid and fluid variability had better visual outcomes with fewer rescues SOL-R prospectively excludes subjects with early persistent retinal fluid and fluid variability, with preliminary analysis indicating ~20% of otherwise eligible subjects excluded from SOL-R randomization for these reasons SOL-R primary endpoint moved to Week 40 (from Week 56) to ensure all subjects complete primary efficacy visit before the interim safety analysis in accordance with the FDA-aligned masking plan, with key secondary endpoints at Weeks 56 and 96 SOL-X enrollment continues with plans to implement every 48-week dosing in the open-label protocol based on the durability shown in SOL-1 HELIOS-3 Phase 3 Diabetic Retinopathy trial enrollment progressing Commercial readiness activities accelerated with investments in commercial infrastructure, market access planning, and launch execution capabilities Ocular appoints Riad Sherif, MD, to Board of Directors, bringing extensive global commercial experience at Alcon, Novartis, Sanofi, and Oculis Cash balance of $530.6 million as of September 30, 2026, with expected runway into 2028 BEDFORD, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights including upcoming NDA submission plans for AXPAXLI™ (also known as OTX-TKI), its investigational product candidate for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinal diseases.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 6, 2026

news preview

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4 and potential 2027 launch. The market is pricing in $1.26 billion in peak U.S. sales for OCUL after competitor advances, lost takeover premium, and rising cash burn.

news source

Seeking Alpha • Oct 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ocular Therapeutix Inc.

Open an M1 investment account to buy and sell Ocular Therapeutix Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OCUL on M1